{"entity":{"type":"insider","cik":"0001532217","url":"/insider/0001532217","json_url":"/insider/0001532217.json","name":"Heberlig Chris","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":24,"n_filings":9,"first":"2012-02-29","last":"2015-03-13","span_basis":"filed_date"},"name_variants":[{"name":"Heberlig Chris","source":"filing","n_filings":9,"first_seen":"2012-02-29","last_seen":"2015-03-13"}],"transactions":[{"id":8263398,"accession":"0001246360-15-001488","txn_seq":8,"anchor":"line-8","filing_url":"/filing/0001246360-15-001488","line_url":"/filing/0001246360-15-001488","is_derivative":false,"issuer_cik":"0000911326","issuer_name":"SYNAGEVA BIOPHARMA CORP","issuer_ticker":"GEVA","issuer_name_source":null,"issuer_url":"/issuer/0000911326","owner_cik":"0001532217","owner_name":"Heberlig Chris","owner_display_name":"Heberlig Chris","owner_url":"/insider/0001532217","role":"Officer (SVP, Finance and Business Ops)","role_mark":"O","role_mark_label":"Officer (SVP, Finance and Business Ops)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP, Finance and Business Ops.","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":7500.0,"shares_display":"7,500","price_per_share":103.16536,"price_display":"103.17","price_state":"stated","total_value":773740.2,"total_display":"773,740.20","total_whole":"773,740","shares_owned_after":2200.0,"shares_owned_after_display":"2,200","ownership_form":"D","is_10b5_1":null,"transaction_date":"2015-03-11","filed_date":"2015-03-13","scope":"insider","n_lines":6},{"id":6752357,"accession":"0001246360-14-004791","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0001246360-14-004791","line_url":"/filing/0001246360-14-004791","is_derivative":false,"issuer_cik":"0000911326","issuer_name":"SYNAGEVA BIOPHARMA CORP","issuer_ticker":"GEVA","issuer_name_source":null,"issuer_url":"/issuer/0000911326","owner_cik":"0001532217","owner_name":"Heberlig Chris","owner_display_name":"Heberlig Chris","owner_url":"/insider/0001532217","role":"Officer (Group Vice President, Finance)","role_mark":"O","role_mark_label":"Officer (Group Vice President, Finance)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Group Vice President, Finance","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":6100.0,"shares_display":"6,100","price_per_share":91.14271475409836,"price_display":"91.14","price_state":"stated","total_value":555970.56,"total_display":"555,970.56","total_whole":"555,971","shares_owned_after":1760.0,"shares_owned_after_display":"1,760","ownership_form":"D","is_10b5_1":null,"transaction_date":"2014-12-29","filed_date":"2014-12-30","scope":"insider","n_lines":4},{"id":7019101,"accession":"0001246360-14-001795","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0001246360-14-001795","line_url":"/filing/0001246360-14-001795","is_derivative":false,"issuer_cik":"0000911326","issuer_name":"SYNAGEVA BIOPHARMA CORP","issuer_ticker":"GEVA","issuer_name_source":null,"issuer_url":"/issuer/0000911326","owner_cik":"0001532217","owner_name":"Heberlig Chris","owner_display_name":"Heberlig Chris","owner_url":"/insider/0001532217","role":"Officer (Group Vice President, Finance)","role_mark":"O","role_mark_label":"Officer (Group Vice President, Finance)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Group Vice President, Finance","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":7670.0,"shares_display":"7,670","price_per_share":98.564814863103,"price_display":"98.56","price_state":"stated","total_value":755992.13,"total_display":"755,992.13","total_whole":"755,992","shares_owned_after":3229.0,"shares_owned_after_display":"3,229","ownership_form":"D","is_10b5_1":null,"transaction_date":"2014-03-12","filed_date":"2014-03-14","scope":"insider","n_lines":3},{"id":5024585,"accession":"0001246360-13-003624","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0001246360-13-003624","line_url":"/filing/0001246360-13-003624#line-5","is_derivative":false,"issuer_cik":"0000911326","issuer_name":"SYNAGEVA BIOPHARMA CORP","issuer_ticker":"GEVA","issuer_name_source":null,"issuer_url":"/issuer/0000911326","owner_cik":"0001532217","owner_name":"Heberlig Chris","owner_display_name":"Heberlig Chris","owner_url":"/insider/0001532217","role":"Officer (Vice President, Finance)","role_mark":"O","role_mark_label":"Officer (Vice President, Finance)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Vice President, Finance","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2029.0,"shares_display":"2,029","price_per_share":48.26,"price_display":"48.26","price_state":"stated","total_value":97919.54,"total_display":"97,919.54","total_whole":"97,920","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"D","is_10b5_1":null,"transaction_date":"2013-07-16","filed_date":"2013-07-17","scope":"insider"},{"id":5024580,"accession":"0001246360-13-003624","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001246360-13-003624","line_url":"/filing/0001246360-13-003624#line-4","is_derivative":false,"issuer_cik":"0000911326","issuer_name":"SYNAGEVA BIOPHARMA CORP","issuer_ticker":"GEVA","issuer_name_source":null,"issuer_url":"/issuer/0000911326","owner_cik":"0001532217","owner_name":"Heberlig Chris","owner_display_name":"Heberlig Chris","owner_url":"/insider/0001532217","role":"Officer (Vice President, Finance)","role_mark":"O","role_mark_label":"Officer (Vice President, Finance)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Vice President, Finance","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":495.0,"shares_display":"495","price_per_share":49.15,"price_display":"49.15","price_state":"stated","total_value":24329.25,"total_display":"24,329.25","total_whole":"24,329","shares_owned_after":2029.0,"shares_owned_after_display":"2,029","ownership_form":"D","is_10b5_1":null,"transaction_date":"2013-07-15","filed_date":"2013-07-17","scope":"insider"},{"id":2256979,"accession":"0001246360-12-005018","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001246360-12-005018","line_url":"/filing/0001246360-12-005018","is_derivative":false,"issuer_cik":"0000911326","issuer_name":"SYNAGEVA BIOPHARMA CORP","issuer_ticker":"GEVA","issuer_name_source":null,"issuer_url":"/issuer/0000911326","owner_cik":"0001532217","owner_name":"Heberlig Chris","owner_display_name":"Heberlig Chris","owner_url":"/insider/0001532217","role":"Officer (Vice President, Finance)","role_mark":"O","role_mark_label":"Officer (Vice President, Finance)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Vice President, Finance","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":4000.0,"shares_display":"4,000","price_per_share":45.9263,"price_display":"45.93","price_state":"stated","total_value":183705.2,"total_display":"183,705.20","total_whole":"183,705","shares_owned_after":1605.0,"shares_owned_after_display":"1,605","ownership_form":"D","is_10b5_1":null,"transaction_date":"2012-12-19","filed_date":"2012-12-21","scope":"insider","n_lines":2},{"id":2764232,"accession":"0001246360-12-004168","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001246360-12-004168","line_url":"/filing/0001246360-12-004168","is_derivative":false,"issuer_cik":"0000911326","issuer_name":"SYNAGEVA BIOPHARMA CORP","issuer_ticker":"GEVA","issuer_name_source":null,"issuer_url":"/issuer/0000911326","owner_cik":"0001532217","owner_name":"Heberlig Chris","owner_display_name":"Heberlig Chris","owner_url":"/insider/0001532217","role":"Officer (Vice President, Finance)","role_mark":"O","role_mark_label":"Officer (Vice President, Finance)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Vice President, Finance","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":4000.0,"shares_display":"4,000","price_per_share":49.655,"price_display":"49.66","price_state":"stated","total_value":198620.0,"total_display":"198,620.00","total_whole":"198,620","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"D","is_10b5_1":null,"transaction_date":"2012-10-17","filed_date":"2012-10-19","scope":"insider","n_lines":2},{"id":2223763,"accession":"0001246360-12-003705","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001246360-12-003705","line_url":"/filing/0001246360-12-003705","is_derivative":false,"issuer_cik":"0000911326","issuer_name":"SYNAGEVA BIOPHARMA CORP","issuer_ticker":"GEVA","issuer_name_source":null,"issuer_url":"/issuer/0000911326","owner_cik":"0001532217","owner_name":"Heberlig Chris","owner_display_name":"Heberlig Chris","owner_url":"/insider/0001532217","role":"Officer (Vice President, Finance)","role_mark":"O","role_mark_label":"Officer (Vice President, Finance)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Vice President, Finance","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1000.0,"shares_display":"1,000","price_per_share":49.1,"price_display":"49.10","price_state":"stated","total_value":49100.0,"total_display":"49,100.00","total_whole":"49,100","shares_owned_after":300.0,"shares_owned_after_display":"300","ownership_form":"D","is_10b5_1":null,"transaction_date":"2012-09-04","filed_date":"2012-09-06","scope":"insider","n_lines":2},{"id":2460279,"accession":"0001246360-12-002670","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001246360-12-002670","line_url":"/filing/0001246360-12-002670","is_derivative":false,"issuer_cik":"0000911326","issuer_name":"SYNAGEVA BIOPHARMA CORP","issuer_ticker":"GEVA","issuer_name_source":null,"issuer_url":"/issuer/0000911326","owner_cik":"0001532217","owner_name":"Heberlig Chris","owner_display_name":"Heberlig Chris","owner_url":"/insider/0001532217","role":"Officer (Vice President, Finance)","role_mark":"O","role_mark_label":"Officer (Vice President, Finance)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Vice President, Finance","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1000.0,"shares_display":"1,000","price_per_share":35.733,"price_display":"35.73","price_state":"stated","total_value":35733.0,"total_display":"35,733.00","total_whole":"35,733","shares_owned_after":200.0,"shares_owned_after_display":"200","ownership_form":"D","is_10b5_1":null,"transaction_date":"2012-06-01","filed_date":"2012-06-05","scope":"insider","n_lines":2},{"id":3158176,"accession":"0001181431-12-012793","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001181431-12-012793","line_url":"/filing/0001181431-12-012793#line-2","is_derivative":false,"issuer_cik":"0000911326","issuer_name":"SYNAGEVA BIOPHARMA CORP","issuer_ticker":"GEVA","issuer_name_source":null,"issuer_url":"/issuer/0000911326","owner_cik":"0001532217","owner_name":"Heberlig Chris","owner_display_name":"Heberlig Chris","owner_url":"/insider/0001532217","role":"Officer (Vice President, Finance)","role_mark":"O","role_mark_label":"Officer (Vice President, Finance)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Vice President, Finance","security_title":"Common Stock, $0.001 par value","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":4500.0,"shares_display":"4,500","price_per_share":36.88,"price_display":"36.88","price_state":"stated","total_value":165960.0,"total_display":"165,960.00","total_whole":"165,960","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"D","is_10b5_1":null,"transaction_date":"2012-02-27","filed_date":"2012-02-29","scope":"insider"}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":24,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":0,"open_market":true},{"code":"S","label":"Open-market sale","n":24,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":24},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0000911326","name":"SYNAGEVA BIOPHARMA CORP","url":"/issuer/0000911326","role":"Officer (SVP, Finance and Business Ops)","n_filings":9,"first_seen":"2012-02-29","last_seen":"2015-03-13"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001532217","retrieved_at":"2026-08-24T22:29:39+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-21","last_ingest":"2026-08-22T05:23:40.159918+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}